Q-omics provides the consensus-scored PPY profile across patient tissues and cancer cell-line models. PPY expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PPY is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, PPY RNA expression shows 9,417 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, COAD, and THYM as cancer lineages where PPY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPY survival associations across molecular data types. PPY RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPY RNA expression–survival associations across cancer types. High PPY expression shows unfavorable associations in UVM, ACC, PCPG, KIRP and THCA, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for PPY RNA expression.
This table summarizes PPY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPY shows lower tumor expression in COAD, THCA, KICH and READ and higher tumor expression in HNSC and KIRC. The COAD box plot shows higher PPY RNA expression in normal versus tumor tissue (log2 FC = −0.806, t-test p < 0.001).
This table shows molecular features associated with PPY in patient tissues and cancer cell lines. In patient samples, PPY shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
